eISSN: 2300-6722
ISSN: 1899-1874
Medical Studies/Studia Medyczne
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
1/2024
vol. 40
 
Share:
Send email
Share:
abstract:
Original paper

Serum level of osteoprotegerin in patients with Parkinson’s disease: a preliminary study

Marta Piaścik-Gromada
1
,
Katarzyna Bocian
2
,
Grażyna Korczak-Kowalska
2
,
Marta Leńska-Mieciek
1
,
Urszula Fiszer
1
,
Małgorzata Michałowska
1

  1. Department of Neurology and Epileptology, Centre of Postgraduate Medical Education, Orłowski Hospital, Warsaw, Poland
  2. Department of Immunology, Faculty of Biology, University of Warsaw, Warsaw, Poland
Medical Studies/Studia Medyczne 2024; 40 (1): 33–37
DOI: https://doi.org/10.5114/ms.2024.137594
Online publish date: 2024/03/28
View full text Get citation
 
PlumX metrics:
Introduction:
Osteoprotegerin (OPG) has recently been suggested to be involved in the pathophysiology of Parkinson’s disease (PD).

Aim of the research:
To compare serum OPG levels in PD patients versus controls with mild headache or back pain (CG1) and acute ischaemic stroke (CG2) and evaluate the relationship between serum OPG level and 1) PD duration, 2) parathyroid hormone (PTH), vitamin D [25(OH)D], total calcium and 3) serum total cholesterol (TC), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglyceride levels.

Material and methods:
In the included 45 PD patients – 20 with initial PD (iPD) and 25 with advanced PD (aPD) and 50 controls (20 CG1, 30 CG2) – we measured serum OPG levels using a sandwich enzyme-linked immunosorbent assay and analysed data applying Student’s t, Mann-Whitney, c2 tests, Pearson’s correlation and linear regression analysis.

Results:
OPG serum level was lower in iPD compared to CG2 subjects (p = 0.026). OPG level depended on the duration of PD (p < 0.01) and TC level (p < 0.03) in PD patients, on 25(OH)D level (p < 0.04) in CG1 and on TC (p < 0.05) and PTH (p < 0.01) levels in CG2.

Conclusions:
Our results indicate that serum OPG level increases with PD duration and is associated with serum TC level in PD and ischaemic stroke patients.

keywords:

stroke, Parkinson’s disease, osteoprotegerin, cholesterol
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.